# China NMPA Drug Inspection - Hebei Quantai Pharmaceutical Co., Ltd. - Woody Scent

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hebei-quantai-pharmaceutical-co-ltd/63853ee1-d1df-458d-9c25-ed20a2523fc6/
Source feed: China

> China NMPA drug inspection for Hebei Quantai Pharmaceutical Co., Ltd. published December 06, 2021. Drug: Woody Scent. In December 2021, the National Medical Products Administration (NMPA) issued Announcement No. 96 regarding two batches o

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: National Medical Products Administration Announcement No. 96 of 2021 Regarding Two Batches of Drugs That Did Not Meet Regulations
- Company Name: Hebei Quantai Pharmaceutical Co., Ltd.
- Publication Date: 2021-12-06
- Drug Name: Woody Scent
- Inspection Finding: Total ash content does not meet regulations
- Action Taken: Risk control measures such as suspending sales and use, recalling products, investigating the reasons for non-compliance and making concrete rectifications, and initiating investigations into suspected illegal activities involving the production and sale of counterfeit and substandard drugs.
- Summary: In December 2021, the National Medical Products Administration (NMPA) issued Announcement No. 96 regarding two batches of traditional Chinese medicine that failed to meet national quality standards. The affected products were labeled as being manufactured by Hebei Quantai Pharmaceutical Co., Ltd. and included one batch of Atractylodes lancea and one batch of Aucklandia lappa. Laboratory testing conducted by provincial institutes in Hubei and Qinghai identified significant quality failures: the Atractylodes lancea failed content determination requirements for active ingredients, while the Aucklandia lappa exceeded permitted levels for total ash content, which serves as a measure of product purity. A key finding of the investigation was that the labeled manufacturer, Hebei Quantai Pharmaceutical Co., Ltd., did not actually produce these batches, suggesting the products are counterfeit. Operating under the Drug Administration Law of the People's Republic of China, the NMPA has mandated immediate risk control measures, including the suspension of sales and use, and a comprehensive recall of the drugs. Regulatory authorities are now required to investigate the illegal production and sale of these substandard products, trace their source, and publicly disclose the findings of their investigations to ensure public safety.

Company: https://www.globalkeysolutions.net/companies/hebei-quantai-pharmaceutical-co-ltd/4c04ac30-e7a4-4890-b9aa-9e8a86d672cd/